Related Experiment Video
Updated: Apr 19, 2026
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
Myeloperoxidase propagates damage and is a potential therapeutic target for subacute stroke
Reza Forghani1, Hyeon Ju Kim2, Gregory R Wojtkiewicz2
11] Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA [2] Division of Neuroradiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract:
Few effective treatment options exist for stroke beyond the hyperacute period. Radical generation and myeloperoxidase (MPO) have been implicated in stroke. We investigated whether pharmacologic reduction or gene deletion of this highly oxidative enzyme reduces infarct propagation and improves outcome in the transient middle cerebral artery occlusion mouse model (MCAO). Mice were treated with 4-aminobenzoic acid hydrazide (ABAH), a specific irreversible MPO inhibitor. Three treatment regimens were used: (1) daily throughout the 21-day observational period, (2) during the acute stage (first 24 hours), or (3) during the subacute stage (daily starting on day 2). We found elevated MPO activity in ipsilateral brain 3 to 21 days after ischemia. 4-Aminobenzoic acid hydrazide reduced enzyme activity by 30% to 40% and final lesion volume by 60% (P<0.01). The MPO-knockout (KO) mice subjected to MCAO also showed a similar reduction in the final lesion volume (P<0.01). The ABAH treatment or MPO-KO mice also improved neurobehavioral outcome (P<0.001) and survival (P=0.01), but ABAH had no additional beneficial effects in MPO-KO mice, confirming specificity of ABAH. Interestingly, inhibiting MPO activity during the subacute stage recapitulated most of the therapeutic benefit of continuous MPO inhibition, suggesting that MPO-targeted therapies could be useful when given after 24 hours of stroke onset.
Insights
Myeloperoxidase (MPO) inhibition reduces stroke damage and improves outcomes. Targeting MPO, even after 24 hours, offers therapeutic benefits for stroke recovery.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Limited effective stroke treatments exist beyond the initial hyperacute phase.
- Reactive oxygen species generation and myeloperoxidase (MPO) are implicated in stroke pathology.
Purpose of the Study:
- To investigate if reducing MPO activity, pharmacologically or via gene deletion, mitigates stroke-induced infarct propagation and improves outcomes.
- To evaluate the therapeutic potential of MPO inhibition in a mouse model of ischemic stroke.
Main Methods:
- Utilized the transient middle cerebral artery occlusion (MCAO) mouse model.
- Administered 4-aminobenzoic acid hydrazide (ABAH), an MPO inhibitor, across different treatment regimens (continuous, acute, subacute).
- Assessed MPO activity, lesion volume, neurobehavioral outcomes, and survival rates.
Main Results:
- Elevated MPO activity was observed in the ipsilateral brain post-ischemia.
- ABAH treatment significantly reduced MPO activity (30-40%) and infarct lesion volume (60%).
- MPO-knockout mice exhibited similar reductions in lesion volume and improved neurobehavioral outcomes and survival.
- Subacute MPO inhibition demonstrated substantial therapeutic benefits, comparable to continuous inhibition.
Conclusions:
- Pharmacologic inhibition or genetic deletion of MPO effectively reduces infarct size and improves functional outcomes after stroke.
- MPO plays a critical role in post-stroke injury progression.
- MPO-targeted therapies hold promise for treating stroke, even when initiated in the subacute phase (after 24 hours).
Related Concept Videos
01:15Ischemic Stroke ll: Pathophysiology
01:29Hemorrhagic Stroke ll: Pathophysiology
01:25Secondary Spinal Cord Injury llI: Pathophysiology